These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15575342)

  • 1. Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patients.
    Testa R; Bonfigli AR; Sirolla C; Boemi M; Manfrini S; Mari D; Testa I; Sacchi E; Franceschi C
    Diabetes Nutr Metab; 2004 Aug; 17(4):217-21. PubMed ID: 15575342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein is directly related to plasminogen activator inhibitor type 1 (PAI-1) levels in diabetic subjects with the 4G allele at position -675 of the PAI-1 gene.
    Testa R; Bonfigli AR; Sirolla C; Marra M; Boemi M; Mari D; Sacchi E; Dolci A; Catalano A; Procopio A; Ceriello A
    Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):220-6. PubMed ID: 17433639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus.
    Funk M; Endler G; Exner M; Marculescu R; Endler L; Abrahamian H; Mauler H; Grimm A; Raith M; Mannhalter C; Prager R; Irsigler K; Wagner OF
    Wien Klin Wochenschr; 2005 Oct; 117(19-20):707-10. PubMed ID: 16416371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province].
    Liu SQ; Xue YM; Yang GC; He FY; Zhao XS
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Aug; 24(8):904-7. PubMed ID: 15321757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
    Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
    Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
    Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
    Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.
    Ezzidi I; Mtiraoui N; Chaieb M; Kacem M; Mahjoub T; Almawi WY
    Diabetes Metab; 2009 Jun; 35(3):214-9. PubMed ID: 19419896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
    Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
    Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
    Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
    Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
    Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
    Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
    Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
    Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
    Kinik ST; Ataç FB; Verdi H; Cetintaş S; Sahin FI; Ozbek N
    Clin Endocrinol (Oxf); 2005 May; 62(5):607-10. PubMed ID: 15853833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
    Grancha S; Estellés A; Tormo G; Falco C; Gilabert J; España F; Cano A; Segui R; Aznar J
    Thromb Haemost; 1999 Apr; 81(4):516-21. PubMed ID: 10235431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype.
    Estellés A; Dalmau J; Falcó C; Berbel O; Castelló R; España F; Aznar J
    Thromb Haemost; 2001 Aug; 86(2):647-52. PubMed ID: 11522017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction.
    Fu L; Jin H; Song K; Zhang C; Shen J; Huang Y
    Chin Med J (Engl); 2001 Mar; 114(3):266-9. PubMed ID: 11780311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
    Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
    Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients.
    Bonfigli AR; Pieri C; Manfrini S; Testa I; Sirolla C; Ricciotti R; Marra M; Compagnucci P; Testa R
    Diabetes Nutr Metab; 2001 Apr; 14(2):71-7. PubMed ID: 11383676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes.
    Mansfield MW; Stickland MH; Grant PJ
    Thromb Haemost; 1995 Oct; 74(4):1032-4. PubMed ID: 8560407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance.
    Sartori MT; Vettor R; De Pergola G; De Mitrio V; Saggiorato G; Della Mea P; Patrassi GM; Lombardi AM; Fabris R; Girolami A
    Thromb Haemost; 2001 Nov; 86(5):1161-9. PubMed ID: 11816701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension.
    Roncal C; Orbe J; Rodriguez JA; Belzunce M; Beloqui O; Diez J; Páramo JA
    Cardiovasc Res; 2004 Jul; 63(1):176-85. PubMed ID: 15194475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.